Absorbed doses in humans from 188Re-Rituximab in the free form and bound to superparamagnetic iron oxide nanoparticles: Biodistribution study in mice

Absorbed doses to human organs from Re-188-Rituximab in the free form and bound to superparamagnetic iron oxide nanoparticles were predicted from results of the radiopharmaceutical biodistribution studies in mice by the RADAR method. Overall, equivalent and effective doses to human organs from the radiopharmaceutical on the nanoparticles were higher because of the enhanced permeability and retention effect. Liver, spleen and kidneys received higher equivalent doses than other organs (5.29, 3.70 and 3.06 mSv/MBq, respectively, for the free radiopharmaceutical and 6.12, 3.96 and 3.93 mSv/MBq for the drug on the nanoparticles).